ST-Elevation Myocardial Infarction clinical trials at UCLA
3 in progress, 1 open to eligible people
Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease
open to eligible people ages 18 years and up
COMPLETE-2 is a prospective, multi-centre, randomized controlled trial comparing a strategy of physiology-guided complete revascularization to angiography-guided complete revascularization in patients with acute ST-segment elevation myocardial infarction (STEMI) or non-ST-segment elevation myocardial infarction (NSTEMI) and multivessel coronary artery disease (CAD) who have undergone successful culprit lesion Percutaneous Coronary Intervention (PCI). COMPLETE-2 OCT is a large scale, prospective, multi-centre, observational, imaging study of patients with STEMI or NSTEMI and multivessel CAD in a subset of eligible COMPLETE-2 patients.
Los Angeles 5368361, California 5332921 and other locations
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Sorry, in progress, not accepting new patients
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Los Angeles 5368361, California 5332921 and other locations
Can Escalation Reduce Acute Myocardial Infarction Mortality in Cardiogenic Shock
Sorry, accepting new patients by invitation only
The CERAMICS study is designed to more clearly delineate the current care of acute myocardial infarction with cardiogenic shock (AMICS) patients who are treated with mechanical circulatory support (MCS) devices in the United States with significant experience in MCS, all of whom have the capability of MCS escalation on-site. Study enrollment is targeted at 120 patients at 20 hospital sites, evaluating clinical outcomes, and focusing on outcomes MCS escalation decision making and ICU level management.
Los Angeles 5368361, California 5332921 and other locations
Our lead scientists for ST-Elevation Myocardial Infarction research studies include Eric H. Yang, MD Rushi Parikh, MD.
Last updated: